GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Organovo Holdings Inc (NAS:ONVO) » Definitions » PB Ratio

ONVO (Organovo Holdings) PB Ratio : 8.31 (As of Apr. 04, 2025)


View and export this data going back to 2011. Start your Free Trial

What is Organovo Holdings PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2025-04-04), Organovo Holdings's share price is $2.12. Organovo Holdings's Book Value per Share for the quarter that ended in Dec. 2024 was $0.26. Hence, Organovo Holdings's PB Ratio of today is 8.31.

The historical rank and industry rank for Organovo Holdings's PB Ratio or its related term are showing as below:

ONVO' s PB Ratio Range Over the Past 10 Years
Min: 0.49   Med: 2.8   Max: 30.59
Current: 8.15

During the past 13 years, Organovo Holdings's highest PB Ratio was 30.59. The lowest was 0.49. And the median was 2.80.

ONVO's PB Ratio is ranked worse than
88.02% of 1285 companies
in the Biotechnology industry
Industry Median: 2.22 vs ONVO: 8.15

During the past 12 months, Organovo Holdings's average Book Value Per Share Growth Rate was -96.60% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -57.10% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -38.10% per year. During the past 10 years, the average Book Value Per Share Growth Rate was -25.30% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Organovo Holdings was -1.30% per year. The lowest was -57.10% per year. And the median was -20.80% per year.

Back to Basics: PB Ratio


Organovo Holdings PB Ratio Historical Data

The historical data trend for Organovo Holdings's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Organovo Holdings PB Ratio Chart

Organovo Holdings Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.01 2.13 1.08 1.24 2.88

Organovo Holdings Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.77 2.88 1.64 2.12 21.64

Competitive Comparison of Organovo Holdings's PB Ratio

For the Biotechnology subindustry, Organovo Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Organovo Holdings's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Organovo Holdings's PB Ratio distribution charts can be found below:

* The bar in red indicates where Organovo Holdings's PB Ratio falls into.


;
;

Organovo Holdings PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Organovo Holdings's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2024)
=2.12/0.255
=8.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Organovo Holdings  (NAS:ONVO) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Organovo Holdings PB Ratio Related Terms

Thank you for viewing the detailed overview of Organovo Holdings's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Organovo Holdings Business Description

Traded in Other Exchanges
Address
11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121
Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.
Executives
David Gobel director 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Vaidehi Joshi director C/O ORGANOVO HOLDINGS, INC., 11555 SORRENTO VALLEY ROAD, SUITE 100, SAN DIEGO CA 92121
Alison Tjosvold Milhous director 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Adam K Stern director STERN AEGIS VENTURES, 810 7TH AVENUE 22ND FLOOR, NEW YORK NY 10019
Thomas Hess officer: President, CFO and PFO 366 MADISON AVE. 12TH FLOOR, NEW YORK NY 10017
Douglas Jay Cohen director 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Thomas E Jurgensen officer: General Counsel & Secretary 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Jeffrey N. Miner officer: Chief Scientific Officer 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Chris Heberlig officer: President and CFO C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Keith Murphy director, officer: Executive Chairman 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Steven George Hughes officer: Chief Medical Officer 6275 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Carolyn Beaver director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
David Shapiro director C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES ST., NEW YORK NY 10013
Presnell Sharon Collins officer: EVP, Research & Development 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Taylor Crouch director, officer: CEO & President 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075